Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia

Tisagenlecleucel (CTL019) is an investigational immunotherapy that involves reprogramming a patient’s own T cells with a transgene encoding a chimeric antigen receptor to identify and eliminate CD19-expressing cells. We previously reported that CTL019 achieved impressive clinical efficacy in patient...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Mueller, Karen Thudium, Maude, Shannon L., Porter, David L., Frey, Noelle, Wood, Patricia, Han, Xia, Waldron, Edward, Chakraborty, Abhijit, Awasthi, Rakesh, Levine, Bruce L., Melenhorst, J. Joseph, Grupp, Stephan A., June, Carl H., Lacey, Simon F.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2017
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5731220/
https://ncbi.nlm.nih.gov/pubmed/28935694
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-06-786129
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados